Milestones and Milestone Payments. 19.1.1 [The Milestones and Milestone Payments for Phase 1 are set out in the following Table.] No Milestone Criteria for achievement Milestone Date Milestone Payment 1 [Insert Milestone Description] [Insert criteria for achievement of Milestone] [Insert the date by which the Milestone must be achieved. This should generally be a period from contract commencement, rather than a fixed date – e.g. ‘Effective Date + 30 days’.] [Insert Milestone payment]
Milestones and Milestone Payments. As set forth in Section 7.1.2, Salix shall pay Lupin the milestone payments set forth on this Schedule 7.1.2 on achievement by Salix or any of its Affiliates or Sublicensees of each of the milestones set forth on Schedule 7.1.2 during the term of this Agreement, within (30) days after the achievement of the relevant milestone. As set forth in the following table: Traveler’s Diarrhea Hepatic Encephalopathy Irritable Bowel Syndrome [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] *Confidential treatment requested; certain information omitted and filed separately with the SEC. Schedule 8.6 Anti-Stacking Third Party
Milestones and Milestone Payments. Milestone Payment to Sequoia ------------------------------- ------------------ In vivo efficacy demonstration $[...***...] IND Filing $[...***...] Initiation of Phase III studies $[...***...] First Marketing Approval $[...***...]
Milestones and Milestone Payments. In accordance with the provisions of Section 2.1(b) of this Agreement, payment of the Milestone Payments to Consultant will be based on the achievement of the specific Milestones specified below. A Milestone shall be achieved for this purpose upon completion of all services and action items described in Exhibit A (in the table titled Program Services Cost) with respect to such Milestone. Milestone Description of Services Total Overall Profit Over The Contract Period % Percentages of Profit Total Profit Due After Milestone Completion $ 14,046.00 1 Marketing 5% Total $ 702.30 2 Application Intake/ Referrals 5% Total $ 702.30 3 Testing Assessment (Math, Reading, Basic Mech) 5% Orientation Processing/ Referrals Test Grading / File Management/ Total $ 702.30 4 Employability Training/ Soft Skills/ 10% Life Skills /Soft Skills Training/ Drug Testing/ Referrals Compile Drug Test Results/ Background Checks/ Total $ 1,404.60 Milestone Description of Services Total Overall Profit Over The Contract Period % Percentages of Profit Total Profit Due After Milestone Completion 5 Interviews/Selection/ Trade Interest Week- Mtg unions 10% OSHA 10 Training Total $ 1,404.60 6 Asbestos Certification 10% Total $ 1,404.60 7 Trade Skills 10% Total $ 1,404.60 8 Application Uptake to Potential Unions 45% Total $ 6,320.70 Overall Totals $ 14,046.00 100% $ 14,046.00 Exhibit D Reimbursable items: ⮚ hand tools; ⮚ uniform t-shirts, hard hats all safety gear for candidates; ⮚ advertising; ⮚ publications; ⮚ travel expense i.e. air, train, taxi; ⮚ car, gas, maintenance/service, repairs; ⮚ rent or lease housing expense; ⮚ office expenses; ⮚ soft skills training facility rental fee; ⮚ on the job training facility monthly rental fee;
Milestones and Milestone Payments. Licensee agrees to make the milestone payments to University as set forth below (the “Milestone Payments”) within forty-five (45) days after the occurrence of each event set forth on such Schedule. Milestone Payment First Phase I Clinical Trial initiated $ 100,000 First Phase III Clinical Trial initiated $ 350,000 First NDA Approval in the U.S $ 500,000 First NDA Equivalent Approval outside of US $ 500,000 Upon first $25,000,000 of commercial sales of any Licensed Products $ 1,000,000 Each of the foregoing payments shall be made only once. Thereafter, no additional Milestone Payments shall be due or payable by Licensee for License Products.
Milestones and Milestone Payments. As set forth in the following table, Salix shall pay Lupin, upon the first achievement by Salix or any of its Affiliates or Sublicensees of each of the specified milestones with respect to a Covered Product during the term of this Agreement, the corresponding milestone payment. Each specified milestone payment shall be payable only once, regardless of the number of times the corresponding milestone may be achieved. Traveler’s Diarrhea Hepatic Encephalopathy Irritable Bowel Syndrome [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] * Confidential treatment requested; certain information omitted and filed separately with the SEC. Schedule 8.6 Anti-Stacking Third Party Alfa Wassermann SpA, its Affiliates, or any of their respective licensees or sublicensees or any other Person claiming rights under any of such Persons Agreement License Agreement, dated June 24, 1996, by and between Alfa Wassermann SpA and Salix Pharmaceuticals, Inc. Schedule 9.2 Recall and Withdrawal Contact Information Lupin: Telephone number: (000) 000-0000 Email address: xxxxxx@xxxxxxxx.xxx Facsimile number: (000) 000-0000 Salix: Telephone number: (000) 000-0000 Email address: Xxxxxx.xxxxxx@xxxxx.xxx Exhibit A Development Plan [*] * Confidential treatment requested; certain information omitted and filed separately with the SEC.
Milestones and Milestone Payments. Upon and subject to the terms and conditions of these Series C Provisions, and Section 2.4.4 of the Stock Purchase Agreement, on or before ten Business Days after the achievement of each milestone (a “Milestone”) described in this Article 29.7.1(a) through (f) (the date of the occurrence or achievement of such Milestone is referred to herein as a “Milestone Date”), Micrologix shall pay to Hybridon the appropriate dollar amount corresponding to the applicable Milestone as set forth below (each, a “Milestone Payment”) through the redemption of a number of Series C Preferred Shares at a price per share equal to the Milestone Redemption Price in accordance with Article 29.9 and/or through the conversion of a number of Series C Preferred Shares into Common Shares having a value based on the then applicable Conversion Price in accordance with Article 29.8 (or a combination thereof) so that in all cases, except as provided by law, the sum of the aggregate Milestone Redemption Price paid and the value of the Common Shares into which the Series C Preferred Shares are converted equals the Milestone Payment set forth below:
Milestones and Milestone Payments. KATANA shall pay Transfert Plus the following Milestone Payments upon the occurrence of the following development milestones for the first Product developped in the field of oncology:
Milestones and Milestone Payments. 7.6 Customer shall pay to CMC each individual Milestone Payment upon the achievement or occurrence of the Milestone Event applicable to the Milestone Payment. Each Milestone Event and its respective Milestone Payment is independent of achievement or occurrence of any of the other Milestones or payment of the other Milestone Payments CMC shall inform Customer upon the achievement of a Milestone as soon as practicable. Customer shall remit each Milestone Payment in immediately available funds to an account designated by CMC in accordance with the payment terms set out in Appendix 2. CMC shall be solely responsible for any and all taxes it incurs with respect to the Milestone Payments. Commercial Supply Agreement – JUNE 2011 37
Milestones and Milestone Payments. Upon and subject to the terms and conditions of these Series D Provisions, and Section 2.4.3 of the Stock Purchase Agreement, on or before ten Business Days after the achievement of each milestone (a “Milestone”) described in this Article 30.6.1(a) through (d) (the date of the occurrence or achievement of such Milestone is referred to herein as a “Milestone Date”), the Company shall pay to the Series D Preferred Holder the appropriate dollar amount corresponding to the applicable Milestone as set forth below (each, a “Milestone Payment”) through the redemption of a number of Series D Preferred Shares at a price per share equal to the Milestone Redemption Price in accordance with Article 30.8 and/or, if the number of Conversion Shares in Article 30.2.2 have not been exceeded, through the conversion of a number of Series D Preferred Shares into Conversion Shares having a value based on the then applicable Conversion Price in accordance with Article 30.7 (or a combination thereof) so that in all cases, except as provided by law, the sum of the aggregate Milestone Redemption Price paid and the value of the Conversion Shares into which the Series D Preferred Shares are converted equals the Milestone Payment set forth below:
